A multidistrict antitrust litigation over the generic drugs Digoxin and Doxycycline has been significantly expanded to include numerous additional class action cases, all stemming from a wide-ranging federal probe that last year led two pharmaceutical executives to plead guilty to price-fixing charges.

The U.S. Judicial Panel on Multidistrict Litigation issued an order April 7 transferring several cases into the MDL that is pending in the U.S. District Court for the Eastern District of Pennsylvania with Judge Cynthia Rufe presiding.

The order additionally expanded the scope of the MDL to include any actions where the plaintiffs, who are either direct or indirect purchasers of generic drugs, are bringing class action claims related to the alleged price-fixing of generic drugs between 2012 and the present, which was the subject of a federal investigation into the industry. That probe eventually led Jeffrey Glazer and Jason Malek, both former executives at Heritage Pharmaceuticals, to plead guilty to conspiring to manipulate drug prices.